StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report sent to investors on Friday.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

Repligen stock opened at $146.06 on Friday. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The firm has a 50 day moving average price of $140.26 and a 200 day moving average price of $143.12. The company has a market cap of $8.18 billion, a price-to-earnings ratio of -394.59, a PEG ratio of 4.29 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the previous year, the firm earned $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. Sell-side analysts predict that Repligen will post 1.52 earnings per share for the current year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds have recently bought and sold shares of the company. Andra AP fonden purchased a new stake in shares of Repligen in the second quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen in the second quarter worth approximately $33,000. UMB Bank n.a. lifted its position in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.